EA025738B9 - Способ конъюгирования водорастворимого полимера с терапевтическим белком (варианты) и полученный модифицированный белок (варианты) - Google Patents
Способ конъюгирования водорастворимого полимера с терапевтическим белком (варианты) и полученный модифицированный белок (варианты)Info
- Publication number
- EA025738B9 EA025738B9 EA201300190A EA201300190A EA025738B9 EA 025738 B9 EA025738 B9 EA 025738B9 EA 201300190 A EA201300190 A EA 201300190A EA 201300190 A EA201300190 A EA 201300190A EA 025738 B9 EA025738 B9 EA 025738B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- water soluble
- soluble polymer
- conjugating
- protein
- therapeutic protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к материалам и способам конъюгации водорастворимого полимера с окисленным углеводным фрагментом терапевтического белка, включающей контактирование окисленного углеводного фрагмента с активированным водорастворимым полимером в условиях, позволяющих конъюгацию. В частности, данное изобретение относится к вышеупомянутым материалам и способам, где водорастворимый полимер содержит активную аминооксигруппу, где оксимная или гидразоновая связь формируется между окисленным углеводным фрагментом и активной аминооксигруппой на водорастворимом полимере и где конъюгация проводится в присутствии нуклеофильного катализатора.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36918610P | 2010-07-30 | 2010-07-30 | |
| PCT/US2011/045873 WO2012016131A1 (en) | 2010-07-30 | 2011-07-29 | Nucleophilic catalysts for oxime linkage |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201300190A1 EA201300190A1 (ru) | 2013-07-30 |
| EA025738B1 EA025738B1 (ru) | 2017-01-30 |
| EA025738B9 true EA025738B9 (ru) | 2018-05-31 |
Family
ID=44629987
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201300190A EA025738B9 (ru) | 2010-07-30 | 2011-07-29 | Способ конъюгирования водорастворимого полимера с терапевтическим белком (варианты) и полученный модифицированный белок (варианты) |
| EA201691292A EA201691292A1 (ru) | 2010-07-30 | 2011-07-29 | Нуклеофильные катализаторы для оксимного связывания |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691292A EA201691292A1 (ru) | 2010-07-30 | 2011-07-29 | Нуклеофильные катализаторы для оксимного связывания |
Country Status (25)
| Country | Link |
|---|---|
| EP (3) | EP4023247A1 (ru) |
| JP (7) | JP6325818B2 (ru) |
| KR (6) | KR102325780B1 (ru) |
| CN (3) | CN103370082A (ru) |
| AR (1) | AR082941A1 (ru) |
| AU (1) | AU2011282571C1 (ru) |
| BR (1) | BR112013001611B1 (ru) |
| CA (1) | CA2806684C (ru) |
| CY (1) | CY1121943T1 (ru) |
| DK (1) | DK2598172T3 (ru) |
| EA (2) | EA025738B9 (ru) |
| ES (1) | ES2731626T3 (ru) |
| HR (1) | HRP20190990T1 (ru) |
| HU (1) | HUE043790T2 (ru) |
| LT (1) | LT2598172T (ru) |
| MX (1) | MX346271B (ru) |
| NZ (1) | NZ605972A (ru) |
| PL (1) | PL2598172T3 (ru) |
| PT (1) | PT2598172T (ru) |
| RS (1) | RS58900B1 (ru) |
| SG (2) | SG187171A1 (ru) |
| SI (1) | SI2598172T1 (ru) |
| TR (1) | TR201908836T4 (ru) |
| TW (1) | TWI534152B (ru) |
| WO (1) | WO2012016131A1 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| CN103370082A (zh) * | 2010-07-30 | 2013-10-23 | 巴克斯特国际公司 | 用于肟键联的亲核性催化剂 |
| EA032056B1 (ru) | 2010-12-22 | 2019-04-30 | Баксалта Инкорпорейтид | Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты) |
| IL235129B (en) * | 2012-04-16 | 2022-06-01 | Cantab Biopharmaceuticals Patents Ltd | Therapeutic compounds for subcutaneous administration |
| AU2013204754C1 (en) * | 2012-05-16 | 2018-10-11 | Takeda Pharmaceutical Company Limited | Nucleophilic Catalysts for Oxime Linkage |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
| CN108884146A (zh) * | 2015-12-03 | 2018-11-23 | 百深公司 | 具有延长的半衰期及降低的配体结合性质的因子viii |
| WO2018017923A1 (en) * | 2016-07-22 | 2018-01-25 | Nektar Therapeutics | Conjugates of a factor viii moiety having an oxime-containing linkage |
| CN111093688A (zh) | 2017-05-15 | 2020-05-01 | 尼克塔治疗公司 | 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法 |
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| SG11202107497XA (en) | 2019-01-23 | 2021-08-30 | Regeneron Pharma | Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors |
| CA3210480A1 (en) | 2021-02-26 | 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54113492A (en) | 1978-02-24 | 1979-09-05 | Sanyo Chem Ind Ltd | Preparation of glucoprotein derivative |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体 |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| WO1994007510A1 (en) | 1992-10-02 | 1994-04-14 | Kabi Pharmacia Ab | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
| WO1994028024A1 (en) * | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| US5574187A (en) * | 1994-10-06 | 1996-11-12 | Uniroyal Chemical Company, Inc. | Process of preparing para substituted phenylamines |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| US6531298B2 (en) | 1997-07-21 | 2003-03-11 | The University Of North Carolina At Chapel Hill | Factor IX antihemophilic factor with increased clotting activity |
| US7074878B1 (en) | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| EP1335931B1 (en) | 2000-05-16 | 2005-12-21 | Lipoxen Technologies Limited | Derivatisation of proteins in aqueous solution |
| AU2004236174B2 (en) | 2001-10-10 | 2011-06-02 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| MXPA04004336A (es) | 2001-11-07 | 2005-05-16 | Nektar Therapeutics Al Corp | Polimeros ramificados y sus conjugados. |
| EP1681303B1 (en) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
| BR0314107A (pt) | 2002-09-11 | 2005-07-19 | Fresenius Kabi De Gmbh | Método de produção de derivados de hidroxialquil amido |
| CA2521784C (en) | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| CN1832762B (zh) * | 2003-08-08 | 2012-09-05 | 弗雷泽纽斯卡比德国有限公司 | 羟烷基淀粉与g-csf的偶联物 |
| BRPI0412671A (pt) | 2003-08-08 | 2006-10-03 | Fresenius Kabi De Gmbh | conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima |
| WO2005014655A2 (en) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| RU2333223C2 (ru) | 2003-08-12 | 2008-09-10 | Лайпоксен Текнолоджиз Лимитед | Альдегидные производные сиаловой кислоты, способы их получения, конъюгаты альдегидных производных сиаловой кислоты и фармацевтическая композиция на их основе |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| KR101237884B1 (ko) | 2003-12-03 | 2013-02-27 | 바이오제너릭스 에이지 | 글리코 peg화 과립구 콜로니 자극인자 |
| ES2593318T3 (es) | 2004-08-12 | 2016-12-07 | Lipoxen Technologies Limited | Derivados de ácido siálico |
| EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| US7884075B2 (en) | 2004-12-27 | 2011-02-08 | Baxter International Inc. | Polymer-factor VIII-von Willebrand factor-conjugates |
| AU2006259225B2 (en) | 2005-06-16 | 2012-05-31 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| CN101535339B (zh) * | 2006-09-01 | 2014-11-12 | 诺沃-诺迪斯克保健股份有限公司 | 改性糖蛋白 |
| EP2059527B1 (en) * | 2006-09-01 | 2014-12-03 | Novo Nordisk Health Care AG | Modified glycoproteins |
| ES2521490T3 (es) | 2006-12-15 | 2014-11-12 | Baxter International Inc. | Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada. |
| EP2201953A4 (en) * | 2007-08-27 | 2011-08-03 | Univ Nagoya Nat Univ Corp | USE OF RIBAVIRIN IN BLOOD COAGULATION DISORDER |
| GB0908393D0 (en) * | 2009-05-15 | 2009-06-24 | Almac Sciences Scotland Ltd | Labelling method |
| ES2590679T3 (es) * | 2009-07-27 | 2016-11-23 | Lipoxen Technologies Limited | Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre |
| KR101832937B1 (ko) * | 2009-07-27 | 2018-02-28 | 박스알타 인코퍼레이티드 | 혈액 응고 단백질 복합체 |
| PE20121643A1 (es) * | 2009-07-31 | 2012-11-25 | Bayer Healthcare Llc | Polipeptidos del factor ix modificados y usos de los mismos |
| CN103370082A (zh) * | 2010-07-30 | 2013-10-23 | 巴克斯特国际公司 | 用于肟键联的亲核性催化剂 |
-
2011
- 2011-07-29 CN CN2011800476351A patent/CN103370082A/zh active Pending
- 2011-07-29 KR KR1020217018874A patent/KR102325780B1/ko active IP Right Grant
- 2011-07-29 SG SG2013005160A patent/SG187171A1/en unknown
- 2011-07-29 KR KR1020217007514A patent/KR102269494B1/ko active IP Right Grant
- 2011-07-29 RS RS20190779A patent/RS58900B1/sr unknown
- 2011-07-29 KR KR1020207006813A patent/KR102172133B1/ko active IP Right Grant
- 2011-07-29 PT PT11741727T patent/PT2598172T/pt unknown
- 2011-07-29 CN CN201810090885.7A patent/CN108079312A/zh active Pending
- 2011-07-29 LT LTEP11741727.9T patent/LT2598172T/lt unknown
- 2011-07-29 CN CN201810089901.0A patent/CN108079311A/zh active Pending
- 2011-07-29 WO PCT/US2011/045873 patent/WO2012016131A1/en active Application Filing
- 2011-07-29 CA CA2806684A patent/CA2806684C/en active Active
- 2011-07-29 SI SI201131742T patent/SI2598172T1/sl unknown
- 2011-07-29 MX MX2013001261A patent/MX346271B/es active IP Right Grant
- 2011-07-29 JP JP2013521998A patent/JP6325818B2/ja active Active
- 2011-07-29 EP EP21207146.8A patent/EP4023247A1/en active Pending
- 2011-07-29 KR KR1020207030594A patent/KR102229967B1/ko active IP Right Grant
- 2011-07-29 HU HUE11741727A patent/HUE043790T2/hu unknown
- 2011-07-29 DK DK11741727.9T patent/DK2598172T3/da active
- 2011-07-29 EP EP11741727.9A patent/EP2598172B1/en active Active
- 2011-07-29 TW TW100126974A patent/TWI534152B/zh active
- 2011-07-29 BR BR112013001611-6A patent/BR112013001611B1/pt active IP Right Grant
- 2011-07-29 NZ NZ60597211A patent/NZ605972A/en unknown
- 2011-07-29 KR KR1020137004971A patent/KR101969601B1/ko active IP Right Grant
- 2011-07-29 EA EA201300190A patent/EA025738B9/ru not_active IP Right Cessation
- 2011-07-29 KR KR1020197010071A patent/KR102088852B1/ko active IP Right Grant
- 2011-07-29 EP EP18208032.5A patent/EP3505186B1/en active Active
- 2011-07-29 AR ARP110102758A patent/AR082941A1/es active IP Right Grant
- 2011-07-29 PL PL11741727T patent/PL2598172T3/pl unknown
- 2011-07-29 ES ES11741727T patent/ES2731626T3/es active Active
- 2011-07-29 TR TR2019/08836T patent/TR201908836T4/tr unknown
- 2011-07-29 EA EA201691292A patent/EA201691292A1/ru unknown
- 2011-07-29 SG SG10201913078SA patent/SG10201913078SA/en unknown
- 2011-07-29 AU AU2011282571A patent/AU2011282571C1/en active Active
-
2015
- 2015-06-11 JP JP2015118007A patent/JP2015164958A/ja not_active Withdrawn
-
2017
- 2017-05-19 JP JP2017099807A patent/JP2017137358A/ja not_active Withdrawn
-
2019
- 2019-03-28 JP JP2019064337A patent/JP6757823B2/ja active Active
- 2019-03-28 JP JP2019064338A patent/JP2019116501A/ja not_active Withdrawn
- 2019-05-31 HR HRP20190990TT patent/HRP20190990T1/hr unknown
- 2019-06-19 CY CY20191100632T patent/CY1121943T1/el unknown
-
2020
- 2020-11-26 JP JP2020196260A patent/JP7054407B2/ja active Active
-
2021
- 2021-12-27 JP JP2021212106A patent/JP7258999B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA025738B9 (ru) | Способ конъюгирования водорастворимого полимера с терапевтическим белком (варианты) и полученный модифицированный белок (варианты) | |
| MX2012001207A (es) | Conjugados proteicos de coagulacion sanguínea. | |
| EA028186B9 (ru) | Способ конъюгации водорастворимого полимера с терапевтическим белком (варианты) и полученный модифицированный белок | |
| NZ611618A (en) | Battery operated solar charged pump kit utilizing an inline submersible pump | |
| EP3093029A8 (en) | Blood coagulation protein conjugates | |
| EA201390940A1 (ru) | Материалы и способы конъюгирования водорастворимого производного жирной кислоты с белком | |
| WO2011012850A3 (en) | Glycopolysialylation of non-blood coagulation proteins | |
| MX2022014125A (es) | Anticuerpos y conjugados de los mismos. | |
| EP4279513A3 (en) | Cytotoxicity-inducing therapeutic agent | |
| WO2010107256A3 (en) | Method for preparing a site-specific physiologically active polypeptide conjugate | |
| EP2244735A4 (en) | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE | |
| WO2009117706A3 (en) | Methods of treatment using anti-mif antibodies | |
| EP4406612A3 (en) | Anti-cd70 antibody drug conjugates | |
| WO2013019681A3 (en) | Selective delivery molecules and methods of use | |
| WO2009140423A3 (en) | Targeted polymer bioconjugates | |
| IN2012DN04908A (ru) | ||
| WO2012138694A3 (en) | Compositions comprising saccharide binding moieties and methods for targeted therapy | |
| IN2012MN02262A (ru) | ||
| IN2012DN02423A (ru) | ||
| WO2008090585A3 (en) | Soluble forms of inclusion complexes of histone deacetylase inhibitors and cyclodextrins, their preparation processes and uses in the pharmaceutical field | |
| DE602008003199D1 (de) | Glucoseisomerase zur behandlung von fructose-unverträglichkeit | |
| WO2009143345A3 (en) | Nucleic acid silencing agent-protein conjugates and use thereof for treating hcv-related disorders | |
| Teo | Nucleic acid delivery using poly (ethylenimine)-based polymers for programmed death-ligand 1 (PD-L1) knockdown in ovarian cancer to enhance immunotherapy | |
| EA202090685A1 (ru) | Нуклеофильные катализаторы для оксимного связывания | |
| 张亚琳 | Lost Old American South——Reflections on The Little Foxes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Publication of the corrected specification to eurasian patent | ||
| PC4A | Registration of transfer of a eurasian patent by assignment | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG TJ TM |